NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

exwannabe,

It sounds like you need some better sources. I recommend JAMA Oncology, UCLA, Brown University, and King’s College.

This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt

— JAMA Oncology (@JAMAOnc) February 15, 2023

Doctors at the Lifespan hospital were on the news again earlier this month highlighting the unmet medical need of GBM and the need for more approved treatment options. They again referred to DCVax-L as a medical “breakthrough” just as they did at the press conference following the publication of the independent peer review.

One of the greatest aspects of immunotherapy such as DCVax-L is that it may be efficacious in combination with a number of other therapies. The pembrolizumab combo is the most exciting and noteworthy combination therapy in my opinion, and I hope that we will see more PD1 combo studies with the DCVax-L platform for cancers beyond nGBM and rGBM.

https://www.lifespan.org/centers-services/brain-and-spine-tumor-center

https://www.wpri.com/health/brain-breakthrough-ri-researchers-working-to-make-progress-against-glioblastoma/

Refocus from distractions and consider the integrity of the science.

https://www.fda.gov/drugs/development-approval-process-drugs

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847